Alkermes' schizophrenia drug meets main goal of late-stage study

(Reuters) - Alkermes Plc said its experimental drug to treat the symptoms of schizophrenia met the main goal of reducing the severity of symptoms of the disease in a late-stage study. The company said it planned to submit a marketing approval application for the drug, aripiprazole lauroxil, to the U.S. Food and Drug Administration in the third quarter of 2014.



via Health News Headlines - Yahoo News http://ift.tt/1kmz8Y2